4 Momentum Stocks to Watch

Harry Boxer  |

Source: Immunogen

These four stocks are moving on news and gaining technical momentum.

Axsome Therapeutics, Inc. jumped $8.60 to $89.57 on 2.6 million shares Wednesday, more than double its average volume. On Monday the biotech company said its experimental treatment for depression met the primary endpoint in a Phase 3 clinical trial. The move popped the stock through the top of an already steep channel rising from the $20 level just two months ago. Watch for $106 next.

Bed Bath & Beyond Inc. gained 84 cents to $17.72 on 10.5 million shares Wednesday. The move followed news of a restructuring in which six senior leaders are leaving the specialty retailer. The stock has been stair-stepping up its rising channel since its mid-August low at $7.31, and the channel top now points to a target of $20-$20.50.

ImmunoGen, Inc. climbed 35 cents to $4.97 on 7.5 million shares Wednesday, more than triple its average volume. On Tuesday the biotech company announced the FDA cleared a trial that could support accelerated approval for its investigational ovarian cancer drug. That news propelled a move that popped the stock out of a falling wedge and through channel and lateral resistance. The next target is $6.

comScore, Inc. rose 29 cents to $5.19 on 1.2 million shares Wednesday. On Tuesday the company announced an agreement to provide Publishers Clearing House with digital audience measurement. The stock has risen sharply from below $2 two months ago, and the channel top points to a target of $7.25.

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

_____

Equities Contributor: Harry Boxer

Source: Equities News

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Trending Articles

Bond Yields Have Risen Well Above Stock Dividend Yields. Are They a Buy?
We're at the Tail End of a Classic Video Game Stock Bust
Is Gold Really the Right Place for Your Money?
How Companies Can Succeed in AI Winter: Jeff Kagan
Utility Investing Is a Steady, Buy-and-Hold Play. Just Not in This Market
Why Nuclear Energy Is Now Part of The Road to Renewables
Our Inflation Nightmare Will Flatline in Six Months
California Wants 100% Electric Vehicles By 2035. Will Its Energy Grid Be Ready?

Market Movers

Sponsored Financial Content